To Evaluate the Efficacy and Safety of JT-003 add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 245 participants.

Also called NCT05296044

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 245 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05296044
Other papers using this trial's data
  • Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial Diabetes & metabolism journal, 2026-03 DOI, PubMed 41151541, PMC12996957 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05296044. Randomized; double masking; primary purpose treatment. Start 2022-04-05 (anticipated); primary completion 2023-10-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
To Evaluate the Efficacy and Safety of JT-003 add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
JT-003
Intervention (Drug)
JT-003 Placebo
Lead sponsor
Jeil Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct05296044
Content hash
05f82da1690cb2646db5dfe761f6c354713b6db6a90ae84e3a65e04dfa034585